Jason McCarthy

Jonathan Aschoff

Vernon Bernardino

Jeffrey Jones

- Moleculin Biotech, Inc. announced the **completion of its Phase 1B/2 (MB-106) clinical trial** for Annamycin in acute myeloid leukemia (AML), reporting a median overall survival of **15 months** for complete remissions and **12 months** for the 2nd line efficacy evaluable population, which significantly exceeds industry expectations of **4-6 months** for relapsed AML patients.  **[1659617_0001437749-25-027798_ex_857342.htm:0]** 
- The company highlighted **no clinically significant cardiotoxicity** in the MB-106 trial and that **50% of subjects achieving complete remission proceeded to a curative bone marrow transplant**.  **[1659617_0001437749-25-027798_ex_857342.htm:1]** 
- Moleculin is progressing its pivotal **Phase 3 MIRACLE trial** for Annamycin in relapsed or refractory AML, aiming to recruit the first **45 enrolled patients before the end of 2025** for safety and efficacy unblinding.  **[1659617_0001437749-25-027798_ex_857342.htm:0]** **[1659617_0001437749-25-027798_ex_857342.htm:1]** 
- Stockholders approved an increase in the authorized common stock from **100,000,000 shares to 500,000,000 shares**, which became effective on **August 21, 2025**.  **[1659617_0001437749-25-027798_mbrx20250826_8k.htm:0]** **[1659617_0001437749-25-027798_ex_857436.htm:0]**

Moleculin Biotech (MBRX)